Trulicity (dulaglutide) / Eli Lilly - LARVOL DELTA

Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence (EASL 2025) - "Primary outcomes were the development of decompensated cirrhosis and all-cause mortality in patients treated with GLP-1 analogs (semaglutide, tirzepatide, dulaglutide, exenatide, lixisenatide) compared to patients treated with bariatric surgery (gastric bypass, sleeve gastrectomy, biliopancreatic diversion with duodenal switch, vertical band gastroplasty)... Out of 545,931 patients with MASLD, 73,339 (13.44%, median 733 days) patients were treated with GLP1 analog, 38,541 (7.06%, median 690 days) sodium-glucose cotransporter 2 (SGLT 2) inhibitors and 29,917 (5.48%, median 832 days) received other weight loss medications (naltrexone, topiramate or phentermine)... GLP-1 analogs are increasingly being used in patients with MASLD. GLP-1 analogs and bariatric surgery reduce the risk of decompensated cirrhosis in obese patients with MASLD. Our results indicate that patients with MASLD treated with GLP-1 analogs have a lower risk of decompensated cirrhosis and better overall..."

Bariatric surgery • Clinical • HEOR • Real-world • Real-world evidence • Surgery • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Obstructive Sleep Apnea • Oncology • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Solid Tumor

Remission of type 2 diabetes in persons with 3rd degree of obesity after 5 years therapy with semaglutide or dulaglutide (ECO 2025) - No abstract available

Clinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders. (PubMed, Neurosci Biobehav Rev) - "We observed that GLP-1 and GLP-1 RAs modulate molecular and cellular changes known to govern the phenomenology of neurodegenerative diseases. Future research should examine the interaction between signaling molecules, neuronal subpopulations, and cognitive effects affected by GLP-1 and GLP-1 RA administration."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease

Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. (PubMed, Int J Impot Res) - "Reports from Q4 2003 to Q1 2024 were analyzed using the OpenVigil 2.1 platform to identify male patients experiencing orgasmic dysfunction, erectile dysfunction, or decreased libido linked to GLP-1 receptor agonists (tirzepatide, semaglutide, dulaglutide, exenatide, lixisenatide, and liraglutide). Despite statistically significant chi-squared values (P < 0.0001), low ROR (0.41, 95% Confidence interval (CI): 0.36-0.48), PRR (0.41, 95% CI: 0.36-0.48), and RRR (0.42, 95% CI: 0.36-0.48) suggest a weak association. These findings underscore the need for monitoring as GLP-1 use expands, though overall patient risk remains low."

Journal • Diabetes • Erectile Dysfunction • Metabolic Disorders • Sexual Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis. (PubMed, Diabetes Ther) - "Tirzepatide demonstrated statistically significantly greater reductions in HbA1c and body weight when compared with selected GLP-1 RAs and placebo in patients with T2DM treated with basal insulin. Overall, the safety profile of tirzepatide was similar to that of GLP-1RAs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (PubMed, Neurol Ther) - " Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease

A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. (PubMed, J Drugs Dermatol) - "Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System, it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia. 2025;24(4):413-415. doi:10.36849/JDD.8605."

Clinical • Retrospective data • Alopecia • Atopic Dermatitis • Dermatology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Type 2 Diabetes Mellitus

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials. (PubMed, Diabetes Obes Metab) - "The magnitude of efficacy for intended therapeutic actions (HbA1c and body weight reduction) varied widely between incretin mimetic glucose-lowering agents. However, larger therapeutic efficacy was not systematically associated with higher GI AE or drug discontinuation rates, indicating better tolerability of the more effective agents/preparations."

Clinical • Journal • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity. (PubMed, Am J Health Syst Pharm) - "This case report describes the use of dulaglutide in the management of mild BED in the setting of comorbid type 2 diabetes and obesity. Further research is necessary to evaluate the long-term effectiveness of GLP-1 RAs in the management of BED and to determine the optimal duration and dose."

Journal • Binge Eating Disorder • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry • Type 2 Diabetes Mellitus

Characterizing Kidney Stone Episodes by GLP-1RA Medication in GLP-1RA Users (AUA 2025) - "INTRODUCTION AND OBJECTIVE: Glucagon-like-peptide 1 receptor agonists (GLP-1RAs) like Semaglutide, Liraglutide, and Dulaglutide have increased in popularity as weight loss medications, but little data exists on how GLP-1RAs affect kidney stone formation. Semaglutide's significant association with lower risk of stone growth compared to other GLP-1RAs emphasizes its potential utility for high stone risk patients. For associations approaching significance, such as Semaglutide's association with decreased risk of surgical intervention, further research is warranted to determine the validity of this correlation controlling for possible confounders. These findings highlight the importance of counseling high stone risk patients requiring GLP-1RA therapy on its potential side effects and realistic expectations regarding stone progression and outcomes, so that a patient-centered discussion guides the choice of GLP1-RA in the management of comorbid conditions."

Renal Calculi

CARDIOVASCULAR OUTCOMES IN NEW USERS OF ONCE-WEEKLY GLP-1 RECEPTOR AGONISTS VS OTHER GLUCOSE-LOWERING THERAPIES AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - Xi Tan (ACC 2025) - "Individual OW GLP-1 RAs dulaglutide, semaglutide, and exenatide extended-release were also compared against specific NIGLT classes: sodium-glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP-4is). The OW GLP-1RA and other NIGLT matched cohorts had 77,712 and 174,620 patients, respectively... Compared with other NIGLTs, OW GLP-1RAs were associated with a significantly reduced risk of CV outcomes. This further supports guideline-recommended use of OW GLP-1RAs for patients with type 2 diabetes and atherosclerotic CV disease."

Medicare • Reimbursement • US reimbursement • Atherosclerosis • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Beyond weight loss: Can Ozempic sharpen your brain, cut dementia risk? (Business Standard) - "The studies suggest that glucagon-like peptide-1 (GLP-1) receptor inhibitors (a drug that binds to a receptor inside a cell) such as Ozempic and Mounjaro could significantly reduce the risk of Alzheimer disease and related dementia, especially among individuals with Type 2 diabetes. An analysis of several clinical trials revealed that these drugs were linked to a 45 per cent lower risk of developing Alzheimer disease and related dementia...According to one of the studies, GLP-1 receptor inhibitors, including semaglutide, dulaglutide, and liraglutide, marketed as Ozempic, Trulicity, and Victoza, respectively, were associated with a reduced risk of dementia in patients with Type 2 diabetes...Another study published in JAMA Neurology reviewed 26 randomised clinical trials involving more than 164,000 participants and found that use of GLP-1 drugs was associated with a reduction in dementia risk....This group faces an elevated risk of Alzheimer’s disease..."

Retrospective data • Alzheimer's Disease • Type 2 Diabetes Mellitus

EFFICACY OF GLUCAGON-LIKE-PEPTIDE-1 AGONISTS FOR WEIGHT LOSS IN ADULTS WITH CONGENITAL HEART DISEASE - Prinston Varghese (ACC 2025) - "Two patients were on tirzepatide 10 mg weekly, one was on dulaglutide 4.5 mg weekly, and one was on oral semaglutide 14 mg daily. Our study suggests that GLP-1 agonists are effective for weight loss and safe to use in adults with congenital heart disease. This study was limited by sample size and retrospective design but provides a basis for designing future prospective studies with a larger cohort."

Clinical • Cardiovascular • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity

Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study. (PubMed, J Diabetes) - "The primary endpoint was met in this study through the demonstration of equivalent efficacy in HbA1c reduction in Chinese adults with T2DM between LY05008 and dulaglutide. Overall, the biosimilar product LY05008 showed comparable safety, PK, and immunogenicity profiles against the reference drug dulaglutide."

Clinical • Journal • Cardiovascular • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Respiratory Diseases • Type 2 Diabetes Mellitus

Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM. (PubMed, Hormones (Athens)) - "Combining dulaglutide with probiotics enhances glycemic control, reduces inflammation, and improves cardiovascular risk factors in T2DM more effectively than dulaglutide alone, likely through gut microbiota modulation. This dual approach offers a promising strategy for T2DM management, though larger long-term trials are needed to confirm cardiovascular benefits."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Hypertension • Inflammation • Metabolic Disorders • Obesity • Severe Hypoglycemia • Type 2 Diabetes Mellitus • TNFA

Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory. (PubMed, Arch Pharm (Weinheim)) - "Collectively, Dula has been demonstrated to protect rats against Tac-induced nephrotoxicity by reducing inflammation, restoring redox homeostasis, and modulation of the miR-22/HMGB-1/TLR4/MyD88/NF-κB trajectory. Dula may be beneficial clinically in preventing Tac-induced renal injury."

IO biomarker • Journal • Oncology • Transplant Rejection • HMGB1 • IL1B • MIR22 • MYD88 • TLR4 • TNFA

Effects of dulaglutide on oxytocin plasma levels in healthy men: a secondary analysis of a randomized, double-blind, placebo-controlled crossover study (ESPE-ESE 2025) - No abstract available

Clinical

Improvement of Glycogenic Hepatopathy With Minimal Corresponding Improvement of Glycemic Control in a Person With Type 1 Diabetes: Case Report and Literature Review. (PubMed, AACE Clin Case Rep) - "She was eventually transitioned to a closed-loop automated insulin delivery system and started dulaglutide for management of obesity...This case raises awareness of an under recognized complication of type 1 diabetes and challenges conventional thinking about factors leading to its resolution. Further investigation into the underlying pathophysiology of glycogenic hepatopathy is needed."

Journal • Autoimmune Hepatitis • Diabetes • Endocrine Disorders • Gastroenterology • Genetic Disorders • Hepatology • Immunology • Inflammation • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Transplant Outcomes (ISHLT 2025) - "Multivariate logistic regression was performed to adjust for factors associated with CLAD.Results We identified 34 patients who initiated GLP-1 receptor agonists (GLP-1RAs) within two years of transplantation, with Dulaglutide and Semaglutide being the most commonly used medications in our cohort...Although not statistically significant, GLP-1RA use is associated with reduced mortality (aOR 0.308; CI: 0.047-2.01; p = 0.219).Conclusion GLP-1RA use is associated with an increased risk of AMR and BOS, potentially reflecting aspiration-related injury to the allograft. Additionally, there was a trend toward improved survival in patients receiving GLP-1RAs, which may be attributed to the cardioprotective properties of these medications."

Antibody-mediated Rejection • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pulmonary Disease • Respiratory Diseases • Transplantation

Safety and Efficacy of Glucagon-Like-Peptide-1 Receptor Agonists in Heart Transplant Patients (ISHLT 2025) - "Distribution according GLP1Ra: semaglutide 17 (65.4%), dulaglutide 6 (23.1%) and liraglutide 3 (11.5%). One in five patients stopped insulin after GLP1Ra initiation. Treatment was well tolerated with few discontinuations."

Clinical • Cardiovascular • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Septic Shock • Transplantation • Type 2 Diabetes Mellitus

Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Patients with Type 2 Diabetes (ADA 2025) - "Available on Friday, June 20, 2025 at 10:30am CDT."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide vs. Dulaglutide in Adults with Type 2 Diabetes (ADA 2025) - No abstract available

Clinical • P3 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide vs. Dulaglutide in Adults with Type 2 Diabetes (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • P3 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Switching from Dulaglutide to Tirzepatide in T2D—Subgroup Analyses of the SURPASS-SWITCH Trial (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Metabolic Disorders • Type 2 Diabetes Mellitus